The $7B Map: Pennsylvania, Virginia, and the MSOs Racing to Be Ready

Pennsylvania and Virginia are the next two adult-use cannabis markets on the East Coast. Together, they're the last expansion window of size left in the region, with combined annual sales projected to reach roughly $7 billion at maturity. The open question isn't whether these markets open. It's which operators are ready when they do.

The timing just shifted. On May 19, 2026, Governor Abigail Spanberger vetoed the Virginia legislation that would have opened adult-use retail on January 1, 2027. Virginia's realistic launch now sits in 2028. That delay reshuffles the order.

Pennsylvania, despite its own legislative gridlock, is now the more plausible first mover. Either way, the operators that capture Day 1 will be the ones already capitalized, licensed, and physically in place. The race is to be ready, not to legalize.

The $7 billion opportunity, sized honestly

Pennsylvania is the larger prize on every dimension. The state has 13 million residents, a $1.2 billion existing medical market across 186 dispensaries, and five legal-cannabis neighbors quietly siphoning consumer dollars. FTI Consulting's base case projects $2.1 billion in Year 1 adult-use sales, with a high case at $2.8 billion. New Jersey border dispensaries have reported that as much as 60% of their customers are Pennsylvania residents. That demand repatriates the moment Pennsylvania retail opens.

Virginia is smaller but underpenetrated in a way that matters. The state's 8.88 million residents are served by only 23 medical dispensaries, capturing roughly 4% of total cannabis demand. The legal market sits alongside an estimated $4.4 billion illicit channel. Projections range from $780 million in Year 1 to $1.9 billion at maturity, with the limited-license model concentrating early revenue in a handful of incumbents.

The knock-on effects spill past the two state lines. New Jersey (projected $1.16 billion in 2025) and New York ($869 million in 2024) will both absorb revenue cannibalization. New Jersey's northern and western dispensaries built customer bases on Pennsylvania crossover traffic, and that traffic reverses when Pennsylvania opens. Maryland, which hit $99 million in monthly sales by April 2026, faces the same dynamic on its Virginia border. The East Coast cannabis map is about to be redrawn, and not every existing operator wins.

The frontrunners

Pennsylvania (largest medical footprint defines the winners)

1. Trulieve. 22+ dispensaries, the largest single-operator footprint in the state. Spent $210,000 on Pennsylvania lobbying in 2024 alone, the largest cannabis-company line item that year. The conviction is plain.

2. Cresco Labs (Sunnyside). 13 dispensaries across Pittsburgh, Philadelphia, and central PA. Disciplined operator with broad geographic coverage and real brand recognition in state.

3. Green Thumb Industries (RISE). The same conservative capital structure that funded GTI's Illinois dominance is available for the Pennsylvania conversion buildout.

4. Curaleaf. Multiple PA stores, the deepest capital markets access among MSOs, and a track record of acquiring conversion-ready assets ahead of launches. The likely consolidator if smaller PA operators stumble.

Virginia (the only five operators that can legally convert)

1. Green Thumb Industries (RISE) — HSA III, Southwest Virginia. The only major MSO posting consistent net income. $114.1 million in 2025 net profit on $1.2 billion in revenue. Conservative balance sheet, a proven Illinois conversion playbook, and a $10M fee that's effectively rounding error. The benchmark.

2. Jushi Holdings (Beyond Hello) — HSA II, Northern Virginia / DC corridor. Six dispensaries in the highest-income, densest consumer region in the state. Premium pricing power, but the thinnest balance sheet of the five incumbents. If launch slips again, the $10M conversion fee gets materially harder to absorb.

3. Verano Holdings (Zen Leaf) — HSA V, Hampton Roads. Bought the license from Cannabist for $90 million in 2024 and has openly told investors it's ready to convert. Zen Leaf already executed adult-use conversion in Maryland and New Jersey. Q1 2025 revenue was down 5% year-over-year, so Verano needs this market more than most.

4. Curaleaf (gLeaf) — HSA IV, Greater Richmond. Acquired the gLeaf Virginia subsidiary for $110 million in early 2026, after initially backing out at the end of 2025. Five retail locations plus 82,000 square feet of cultivation. Largest U.S. cannabis operator by revenue at $1.27 billion. Capital access isn't the constraint.

5. AYR Wellness / New AYR — HSA I, Northwest Virginia / Shenandoah Valley. The wildcard. AYR's Virginia assets went through a foreclosure sale in November 2025, and a restructured entity controlled by senior noteholders now holds the license. Lower-density region, restructured cap table, and real operational questions about Day 1 readiness.

Two states, two models, and the question that matters more than the vote

Most headlines focus on whether each state will legalize. The more consequential question is how. Retail-model design determines whether multi-state operators capture the upside or get cut out entirely.

Virginia is heading toward private retail with hard caps. The vetoed bill, and any 2027 successor, runs a private licensing model with a 350-store cap, a $10 million medical-to-adult-use conversion fee per operator (payable over three years), and a five-license limit per entity for vertical integration. Combined tax rate lands at roughly 12 to 14%. Only five companies hold pharmaceutical processor licenses, one per Health Service Area, and those five will define the early market.

Pennsylvania is still arguing about the model itself. HB 1200, the state-run framework that would have routed sales through the Pennsylvania Liquor Control Board, passed the House by a single vote in May 2025 and was killed 7-3 in the Senate Law and Justice Committee a week later. The bipartisan Laughlin-Street Senate framework and HB 20 both propose private retail under a new Cannabis Control Board, with a 12% excise tax.

The state-run model is the structural loser scenario for MSOs. Under HB 1200, existing medical operators could convert only if state stores ran short, which would relegate private companies to wholesale supply contracts with a single buyer. Brand equity and retail margins collapse under that architecture. Republican Senate resistance to HB 1200, ironically, is the most pro-MSO political force in the state today.

The race isn't to legalize. It's to be ready.

We looked at Maryland's July 2023 launch as the baseline. Roughly 100 existing medical dispensaries converted to dual-use on Day 1. Combined sales hit $1.1 billion in the first 12 months. Ohio replicated the pattern in August 2024 with $90 million in adult-use sales over the first seven weeks. In both states, the operators that captured the launch were the ones with the infrastructure already in place.

The first 12 to 18 months after launch is the highest-margin window the cannabis industry offers. Demand outstrips supply, license caps suppress competition, and consumer loyalty forms before new entrants can build. By the time new licenses issue 18 months later, incumbents have already taken the market.

The MSOs preparing for Virginia and Pennsylvania today aren't really betting on a launch date. They're buying optionality on the only two adult-use markets left worth fighting for on the East Coast, while accepting that the date will slip and the model may change. Whoever holds the conversion license on Day 1 collects the premium that follows.